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Introduction: Erythromelalgia is a rare clinical syndrome characterized by episodic erythema, warmth and intense
burning pain, which commonly involves the extremities. For those affected, this disorder may lead to significant
long-term morbidity. Unfortunately, to date, no definitive therapy is available. This case report describes an Egyptian
child with primary erythromelalgia that manifested at an early age and showed partial response to therapy with
cetirizine hydrochloride. This anecdotal case report may have a diagnostic value for clinicians who have not seen
this disorder.
Case presentation: A 34-month-old previously healthy right-handed Hamitic boy without any significant past medical
history presented at the age of 2 years with episodic bilateral pain in his feet. His mother reported associated warmth
and erythema localized to his feet that never extended beyond his ankle joints. This pain is triggered by exertion and/
or warm temperature exposure and is relieved by cooling measures. The diagnosis of erythromelalgia was made based
on the patient’s medical history and a thorough physical examination during the episodes. No evidence of local or
systemic infection was present. Other causes for the symptoms were excluded by a negative extensive diagnostic
work-up. Our patient did not respond to ibuprofen (15mg/kg/dose) three times a day but partial improvement with
the oral non-sedating antihistaminic cetirizine hydrochloride (2.5mg/kg/once daily) was observed. When the child
stopped cetirizine hydrochloride for 1 month as a test, the symptoms became aggravated and were relieved when
cetirizine therapy was restarted. Cetirizine hydrochloride had not previously been reported to have this effect in children
with erythromelalgia.
Conclusions: Erythromelalgia is a clinical syndrome of which the etiology, diagnosis and management are
controversial. We describe a case of a 34-month-old Egyptian child with primary erythromelalgia that manifested at an
early age. We believe that this is the first Egyptian case report of this kind in the literature. Partial response of this
patient to cetirizine hydrochloride may grant us a new clue to understanding this mysterious condition.
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Erythromelalgia (EM) is a rare disorder in children charac-
terized by episodic erythema, warming and burning pain,
which commonly involves the extremities [1]. EM can be
primary (which may be sporadic or familial) or secondary
to other causes including but not limited to autoimmune
disorders, myeloproliferative and/or neuropathic condi-
tions [2] (Table 1).* Correspondence: abdelazeemhemed@yahoo.com
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bution, and reproduction in any medium, proSymptoms are triggered by physical exertion and/or a
warm environment and can be relieved by cooling. Epi-
sodes may last from minutes to hours. Early recognition
of EM is important but difficult due to the rare nature
of the disorder [3].
Case presentation
Our patient was a 34-month-old right-handed Hamitic
boy who presented with insidious intermittent attacks of
bilateral intense pain, warmth and flushing of feet, each
lasting minutes to hours. The age of onset for these
symptoms was 2 years. His symptoms had the tendencyntral Ltd.El-Mazary This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distri-
vided the original work is properly credited.
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proximally beyond his ankle joints; they were precipitated
and worsened with exercise and/or warm temperature ex-
posure such as covering his legs with blankets and were
abated by cooling measures like cold water. There was no
history of similar conditions in his family or drug intake
before the precipitation of the attacks. He had no history
of previous blood transfusion. He looks well, with no man-
ifestations of acute illness. Physical examinations during
multiple visits revealed: normal vital signs; no pallor, jaun-
dice or cyanosis were present; no organomegaly or lymph-
adenopathies were present; only both his feet appeared
red in color (Figure 1) and warm. Extensive investigations
were done for exclusion of other diseases causing pain
and/or flushing of both lower limbs as well as for exclu-
sion of secondary EM.
In this child, the investigations revealed normal complete
blood count (CBC) with differential, normal serum im-
munoglobulin E (IgE) titre (11IU/mL), normal levels of
serum cholesterol (146mg/dL) and triglycerides (49mg/dL),
normal levels of serum urea (16mg/dL) and serum creatin-
ine (0.7mg/dL), normal liver enzymes (alanine aminotrans-
ferase 22U/L and aspartate aminotransferase 34U/L),
normal serum uric acid (3.7mg/dL), negative antistreptoly-
sin O titre, and normal urine analysis and stool analysis.
The fasting and 2 hours post-prandial blood glucose levels
were 89 and 122mg/dL respectively.
In addition, the results of an X-ray of the bones in
both his feet and legs and a Doppler of the arteries ofboth his lower limbs were normal, normal nerve con-
duction velocities of both peroneal nerves and normal
bone marrow biopsy were present. A pelvic and abdom-
inal sonography and brain computed tomography (CT)
were done and all were normal.
A skin biopsy was performed, showing nonspecific
changes consistent with the diagnosis of primary EM
(Figure 2) in the form of numerous telangiectatic blood
vessels in the capillary dermis associated with sparse
perivascular mononuclear cell infiltrate and some ves-
sels showed swelling of the endothelial lining. The in-
timal thickening and thrombi seen in secondary EM
were lacking.
He received ibuprofen (15mg/kg/dose three times a day)
for 2 to 3 weeks but no relief of his symptoms was
observed, but he did report a partial response to cetirizine
hydrochloride (2.5mg/kg/once daily). When the child
stopped cetirizine hydrochloride for 1 month as a test, his
symptoms became aggravated but were relieved when
cetirizine therapy was restarted; the frequency and severity
of the attacks were reduced. His mother was advised that
he should avoid all conditions that exacerbated his symp-
toms and that she should expose his lower limbs to cold
air (fan) during an attack and avoid his exposure to cold
or ice water to avoid ischemia of both his lower limbs. She
was advised on the benefit of routine follow-up evaluation
in the pediatric clinic for follow-up by CBC and, if neces-
sary, any other investigations needed. Finally, the diagnosis
of primary EM was made based on the clinical history and
examination.
Discussion
In 1878, Mitchell [4] described and named ‘erythromelal-
gia’; the name ‘erythromelalgia’ reflected the characteristic
findings of redness (erythros) and pain (algos) involving
the extremities (melos). Unfortunately, there is at present
no confirmatory diagnostic test and the diagnosis is based
on taking a careful history and physical examination dur-
ing the episodes. With the advent of digital photography,
photographs can be very helpful to document the events
of erythema. Thermography can reveal the increased skin
temperature in the affected area, but this is not necessary
to establish the diagnosis [2,3].
The incidence and prevalence of EM are difficult to cal-
culate due to the patient’s failure to recognize the condition
when the symptoms are mild, and physicians may fail to
make the diagnosis because this is a rare and relatively un-
known disorder. The proposed incidence is 2.5 to 3.3 per
million per year [5], with a prevalence of 18 to 20 per mil-
lion in the Norwegian population [6]. A recent retrospect-
ive study in Sweden reported an incidence of 0.36 cases per
100,000 population [7]. The incidence and prevalence of
EM in Egypt is unknown and it should be noted that this
case may be the first case in Egypt reported.
Figure 1 Photography for our case during an episode.
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with most cases occurring in the fifth and sixth decades;
in early reports, the median age of onset for early-onset
EM was 10 years [5].
After a 37-year analysis of 32 pediatric cases at the Mayo
Clinic, Minnesota, researchers concluded that the majority
of cases were not inherited and that progress of the dis-
ease is variable. No safe or reliable treatment has been
established; EM in the pediatric population is associated
with substantial morbidity and, sometimes, death [8].
In a Norwegian case series [7], the age range in the pri-
mary group (early onset and idiopathic adult onset disease)
was 7 to 76 years, and the age range in the secondary group
(secondary EM) was 18 to 81 years. In a retrospective re-
view of 168 patients with EM examined at the Mayo Clinic
between 1970 and 1994, the median age was 60 years and
the age range was 5 to 91 years [5,8].Figure 2 Skin biopsy of the case.The early age of our child is considered one of the
earliest ages for presentation for primary (or idiopathic)
EM and this is consistent with the few studies that have
reported onset of EM at the age of 3 years or less in
some families [9-11].
The Mayo Clinic series showed a male-to-female ratio
of 1:3, whereas it was 3:2 in a review of 60 cases of EM
due to myeloproliferative disorders [5,7,8].
As there is a relatively well-documented association
between EM and myeloproliferative disorders and sys-
temic mastocytosis, an initial CBC with a differential
count as well as bone marrow examination were done
which revealed normal values. A normal CBC excluded
other hematological disorders including pernicious anemia,
essential thrombocythemia, polycythemia vera, myelodys-
plastic syndrome, and thrombotic and immunologic throm-
bocytopenic purpuras [1,3]. Hemoglobin electrophoresis
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especially sickle cell anemia, which may elucidate the symp-
tomatology of the child when no abnormality can be
detected.
Several authors [5,7] have reported that the onset of
symptoms of EM may precede detectable myeloprolifera-
tive diseases by several years. So our patient was advised on
the benefit of routine follow-up evaluation. EM may be sec-
ondary to connective tissue disorders [2], such as rheuma-
toid arthritis, systemic lupus erythematosus, Sjögren’s
syndrome and vasculitis, but the clinical presentation and
laboratory investigations excluded them because the results
of the autoimmune panel were normal. This autoimmune
panel included: normal CBC and erythrocyte sedimentation
rate, negative rheumatoid factor, and antinuclear, anti-
Smith and anti-deoxyribonucleic acid (DNA) antibodies.
Some drugs (for example bromocriptine), mushroom in-
gestion and mercury poisoning [2,12] were reported to
cause secondary EM and those were excluded by history
and clinical examination.
In our case, there was no X-ray evidence of calcified ar-
teries in his lower limbs. In addition, he had normal blood
pressure, normal values of serum cholesterol and triglycer-
ides levels, and normal blood flow of both lower limbs
through the Doppler which ruled out EM-like syndromes
such as Raynaud’s syndrome and Buerger’s disease.
Neuropathies (including diabetic neuropathies), multiple
sclerosis and spinal cord disease are some of the neuro-
logical disorders associated with EM [2]; these were ex-
cluded through normal urine analysis, fasting and 2 hours
post-prandial blood glucose levels, and normal nerve con-
duction velocity of both peroneal nerves. The results of a
pelvic and abdominal sonography and brain CT, which
were done to exclude oncologic causes especially astrocy-
toma, were normal.
The exact pathological mechanism responsible for
this disorder is unknown, but several theories have been
proposed to explain its pathophysiology including vas-
culopathy and/or neuropathy hypotheses. According to
the microvascular arteriovenous (AV) hypothesis [13,14],
symptoms are caused by tissue hypoxia induced by im-
paired distribution of skin microvascular blood flow with
increased thermoregulatory flow through AV shunts and
an inadequate perfusion. Work done by Mork and col-
leagues [15] supports this hypothesis of increased thermo-
regulatory flow through AV shunts during attacks in
primary EM, whereas Orstavik and colleagues suggested
that EM may be due to hypersensitivity of C-fibers [16].
A prospective study done by Davis et al. [17] suggested
that EM is associated with a neuropathy, primarily small-
fiber, and a vasculopathy with intermittent increased blood
flow and AV shunting. There may be increased local cellu-
lar metabolism. However, it is unclear which one is the ini-
tiating event or primary abnormality.Kim et al. [18] reported mutations in the SCN9A gene,
which encodes the Nav1.7 sodium channel, in patients
with primary EM. Cummins et al. [19] demonstrated that
these mutations in the Nav1.7 channel produce a hyperpo-
larizing shift in activation and slow deactivation causing
the sodium channels to remain open for extended periods
of time.
Dib-Hajj et al. [20,21] demonstrated another F1449V
mutation in the Nav1.7 channel, which also reduces the
firing threshold and produces abnormal repetitive firing
in sensory neurons in primary EM. Nearly a dozen mu-
tations in Nav1.7 have been identified. These mutations
have been found to be a cause of familial EM.
Drenth and Waxman [22], Dib-Hajj et al. [23] and
Min-Tzu and colleagues [24] reported that mutations in
the human SCN9A gene, encoding the α–subunit of the
voltage-gated sodium channel, Nav1.7, were found to be
responsible for primary EM. Three missense mutations of
the SCN9A gene have recently been identified in Taiwanese
patients including a familial (I136V) and two sporadic mu-
tations (I848T, V1316A). V1316A is a novel mutation and
has not been characterized yet. Topologically, I136V is lo-
cated in the DI/S1 segment and both I848T and V1316A
are located in S4-S5 linker region of DII and DIII domains,
respectively.
Overall, these changes reflect the hyperexcitability of
peripheral sensory and sympathetic neurons, which con-
tributes to symptom production in primary EM.
A skin biopsy was done for our child and revealed non-
specific changes as mentioned before; this is consistent with
many studies that revealed the same changes [14,15,25].
A universally effective treatment for primary (or idio-
pathic) EM is still unknown as shown in Table 2. The main-
stay of therapy is support and avoidance of trigger factors.
Local measures include cooling or elevating the extremity
to effectively attenuate or relieve symptoms. Patients should
also be counseled about the use of safe cooling options
such as fans and air conditioning rather than cold water it-
self, as ice or immersing an extremity into an icy water bath
can lead to skin necrosis and ulceration [5,8].
Treatment with medications such as propranolol, gaba-
pentin, tricyclic antidepressants, sodium nitroprusside,
calcium channel blockers and intravenous lidocaine and
oral mexiletine had some symptomatic benefits in a few
cases and mainly in adults not in children [26-31].
Medications that affect voltage-gated sodium channels
show promise, although prostacyclin may provide some
benefit and some patients achieved relief with gabapentin
or high-dose magnesium [32-34]. Some rare patients with
EM may respond well to treatment with carbamazepine
especially those with the Nav1.7channel mutations [35].
Recent studies have indicated that it is possible to pre-
dict the response of patients with EM to treatment with
sodium channel blockers on the basis of atomic-level
Table 2 Response to earlier medications and other treatments in 32 patients presenting to Mayo Clinic with
erythromelalgia [8]
Drugs used No. of patients, response
n Very helpful Somewhat helpful Not helpful
Aspirin 14 1 2 11
NSAIDs (ibuprofen, indomethacin, naproxen) 14 1 0 13
Antidepressants (amitriptyline hydrochloride,
venlafaxine, cyproheptadine hydrochloride)
10 2 2 6
Antihistamines (diphenhydramine, cetirizine hydrochloride, cimetidine) 8 0 0 8
Vasodilators (nitroprusside, nifedipine, diltiazem) 7 1 1 5
Β-blockers (propranolol, atenolol, nadolol) 6 0 1 5
Narcotics (codeine, morphine, fentanyl) 6 0 4 2
Gabapentin 6 2 0 4
Parenteral corticosteroids (oral, intramuscular, intravenous) 6 0 1 5
Topical corticosteroids 5 0 0 5
Physical methods (biofeedback, intrathecal pump, TENS unit) 4 1 1 2
Other anticonvulsants (carbamazepine, phenytoin) 3 0 1 2
Sympathectomy 3 0 1 2
Acetaminophen 3 0 1 2
Other medications* (doxazosin mesylate, capsaicin, ergotamine tartrate,
mexiletine, clonidine, tetracycline, homeopathic)
7 0 0 7
NSAIDs, nonsteroidal anti-inflammatory drugs; TENS, transcutaneous electrical nerve stimulation.
*Each drug given to one patient and all of them gave a “not helpful” response.
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future, it may be possible to genotype patients with EM,
and prospectively predict the response to various drugs via
pharmacogenomics. We could not perform a genetic study
in our case because this was expensive; we depended on
the clear history and the clinical picture for the diagnosis
of our case. Lastly, genetic study may be more valuable in
studies comparing different modalities of therapy.
Antihistamines are often overlooked in the treatment of
EM, but these drugs have potent vascular effects and should
be considered in difficult cases [37]. Published reports
described two remissions with cyproheptadine and three
cases with marked improvement using pizotifen, which are
antihistamines with proven serotonin antagonist effects at
5-HT2 receptors. In its June 2006 newsletter, The Erythro-
melalgia Association (TEA) reported a remission that has
lasted 10 years with a low dose of cyproheptadine [37,38].
The TEA survey indicates that approximately 40% of users
of antihistamines obtain modest improvement in their EM,
whereas 60% do not obtain improvement. One TEA mem-
ber reported marked improvement with variable use of
desloratadine, chlorpheniramine, and diphenhydramine [37].
Regarding the non-sedating antihistaminic, cetirizine
hydrochloride, no improvement was observed in some
previous reports [2,8,37] which is in contradiction to our
case. This may lead us to think about a new theory of
chronic long-standing local allergic reaction which en-
lightens response to cetirizine in our case in spite of anormal serum IgE titre on the basis of atomic-level
structural modeling.
Secondary EM successfully treated with intravenous
immunoglobulin plus treatment of the cause in a female
patient with seronegative polyarthritis has also been re-
ported [39].
Ulceration, necrosis, and gangrene of affected extrem-
ities are possible. Digital necrosis or skin ulceration with
secondary infection can lead to amputation. At least one
patient had near-fatal hypothermia related to the con-
stant cooling required to control symptoms [5,8,37].
Conclusions
EM is a rare clinical syndrome of which the etiology, diag-
nosis and management are controversial. We describe a
case of a 34-month-old Egyptian child with primary EM
that manifested at an early age. We believe that it is one of
the rare cases with early onset of presentation and we be-
lieve it is the first Egyptian case report of this kind in the
literature. Partial response of this case to cetirizine hydro-
chloride may grant us a new clue to understanding this
mysterious condition.
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